Cancer stem cells: Biological functions and therapeutically targeting

International Journal of Molecular Sciences

Volumn 15, Issue 5, 2014, Pages 8169-8185

  Ciurea, Marius Eugen ^a   Georgescu, Ada Maria ^a   Purcaru, Stefana Oana ^a   Artene, Stefan Alexandru ^a   Emami, Ghazaleh Hooshyar ^a   Boldeanu, Mihai Virgil ^b   Tache, Daniela Elise ^a   Dricu, Anica ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b Stem Cell Bank Unit Medico Science SRL   (Romania)

Author keywords

Cancer stem cell; Cancer stem cell markers; Cancer therapy; Signalling pathways; Tumorigenicity

Indexed keywords

ALDEHYDE DEHYDROGENASE; BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN; CD133 ANTIGEN; FIBROBLAST GROWTH FACTOR; HERMES ANTIGEN; MICRORNA; S PHASE KINASE ASSOCIATED PROTEIN 2; SONIC HEDGEHOG PROTEIN; THY 1 ANTIGEN; ANTINEOPLASTIC AGENT;

BMI 1 PATHWAY; CANCER ASSOCIATED FIBROBLAST; CANCER STEM CELL; CELL HETEROGENEITY; CLONOGENIC ASSAY; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE SILENCING; GERMLINE MUTATION; HEDGEHOG PATHWAY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTCH PATHWAY; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84900009633     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15058169     Document Type: Review

References (118)

1. Dick, J.E. Stem cell concepts renew cancer research. Blood 2008, 112, 4793.
2. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
3. Hope, K.J.; Jin, L.; Dick, J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5, 738-743.
4. Passegué, E.; Jamieson, C.H.M.; Ailles, L.E.; Weissman, I.L. Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. USA 2003, 100, 11842-11849.
5. Castelo-Branco, P.; Zhang, C.; Lipman, T.; Fujitani, M.; Hansford, L.; Clarke, I.; Harley, C.B.; Tressler, R.; Malkin, D.; Walker, E. et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin. Cancer Res. 2011, 17, 111-121.
6. Li, C.; Hynes, M.J.; Jing, J. Pancreatic cancer stem cells: New direction for pancreatic cancer treatment. Trends Bio/Pharm. Ind. 2010, 6, 34-40.
7. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68, 4311-4320.
8. Miki, J.; Furusato, B.; Li, H.; Gu, Y.; Takahashi, H.; Egawa, S.; Sesterhenn, I.A.; McLeod, D.G.; Srivastava, S.; Rhim, J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 2007, 67, 3153-3161.
9. Beier, D.; Hau, P.; Proescholdt, M.; Lohmeier, A.; Wischhusen, J.; Oefner, P.J.; Aigner, L.; Brawanski, A.; Bogdahn, U.; Beier, C.P. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67, 4010-4015.
10. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756-760.
11. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5, 67.
12. Tirino, V.; Desiderio, V.; Paino, F.; de Rosa, A.; Papaccio, F.; Fazioli, F.; Pirozzi, G.; Papaccio, G. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011, 6, 2022-2030.
13. Suvà, M.L.; Riggi, N.; Stehle, J.C.; Baumer, K.; Tercier, S.; Joseph, J.M.; Suva, D.; Clement, V.; Provero, P.; Cironi, L. et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 2009, 69, 1776-1781.
14. Boveri, T. The Origin of Malignant Tumors; Williams and Wilkins: Baltimore, MD, USA, 1914.
15. Tyzzer, E.E. Tumor immunity. J. Cancer Res. 1916, 1, 125-156.
16. Muller, H.J. Radiation damage to the genetic material. Sci. Prog. 1951, 7, 33-59.
17. Berenblum, I.; Shubik, P. A new, quantitative, approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br. J. Cancer 1947, 1, 383-391.
18. Moolgavkar, S.H.; Knudson, A.G. Mutation and cancer: A model for human carcinogenesis. J. Natl. Cancer Inst. 1981, 66, 1037-1052.
19. Knudson, A.G., Jr. Hereditary cancers of man. Cancer Investig. 1983, 1, 187-193.
20. Knudson, A.G., Jr. Hereditary cancer, oncogene, and antioncogenes. Cancer Res. 1985, 45, 1437-1443.
21. Harbour, J.W.; Lai, S.L.; Whang-Peng, J.; Gazdar, A.F.; Minna, J.D.; Kaye, F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988, 24, 353-357.
22. Lee, W.H.; Shew, J.Y.; Hong, F.D.; Sery, T.W.; Donoso, L.A.; Young, L.J.; Bookstein, R.; Lee, E.Y. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987, 329, 642-645.
23. Nowell, P.C. The clonal evolution of tumor cell populations. Science 1976, 194, 23-28.
24. Hanahan, D.; Weinberg, R. The hallmarks of cancer. Cell 2000, 100, 57-70.
25. Weinberg, R.A. The Biology of Cancer; Taylor & Francis: New York, NY, USA, 2006.
26. Triolo, V.A. Nineteenth century foundations of cancer research advances in tumor pathology, nomenclature, and theories of oncogenesis. Cancer Res. 1965, 25, 76-98.
27. Soto, A.M.; Sonnenschein, C. Emergentism as a default: Cancer as a problem of tissue organization. J. Biosci. 2005, 30, 103-118.
28. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7, 21-33.
29. Rock, J.R.; Randell, S.H.; Hogan, B.L. Airway basal stem cells: A perspective on their roles in epithelial homeostasis and remodeling. Dis. Model. Mech. 2010, 3, 545-556.
30. Rock, J.R.; Onaitis, M.W.; Rawlins, E.L.; Lu, Y.; Clark, C.P.; Xue, Y.; Randell, S.H.; Hogan, B.L.M. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. USA 2009, 106, 12771-12775.
31. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367, 645-648.
32. Van Keymeulen, A.; Blanpain, C. Tracing epithelial stem cells during development, homeostasis, and repair. J. Cell Biol. 2012, 197, 575-584.
33. Moore, M.A.; Williams, N.; Metcalf, D. In vitro colony formation by normal and leukemic human hematopoietic cells: Characterization of the colony forming cells. J. Nat. Cancer. Inst. 1973, 50, 603-623.
34. Dalerba, P.; Cho, R.W.; Clarke, M.F. Cancer stem cells: Models and concepts. Ann. Rev. Med. 2007, 58, 267-284.
35. Shackleton, M.; Quintana, E.; Fearon, E.R.; Morrison, S.J. Heterogeneity in cancer: Cancer stem cells vs. clonal evolution. Cell 2009, 138, 822-829.
36. Dick, J.E. Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. USA 2003, 100, 3547-3549.
37. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res. 2006, 66, 1883.
38. Sell, S. On the stem cell origin of cancer. Am. J. Pathol. 2010, 176, 2584-2594.
39. Pierce, G.B.; Dixon, F.J. The demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 1959, 12, 573-583.
40. Ushijima, T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 2007, 40, 142-150.
41. Ushijima, T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 2005, 5, 223-231.
42. Sell, S. Stem cells in hepato carcinogenesis. Cell Sci. Rev. 2006, 3, 1742-8130.
43. Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 1911, 13, 397-411.
44. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells Nature 2001, 414, 105-111.
45. Odoux, C.; Fohrer, H.; Hoppo, T.; Guzik, L.; Stolz, D.B.; Lewis, D.W.; Gollin, S.M.; Gamblin, T.C.; Geller, D.A.; Lagasse, E. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res. 2008, 68, 6932-6941.
46. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
47. Bapat, S.A. Evolution of cancer stem cells. Semin. Cancer Biol. 2007, 17, 204-213.
48. Chaffer, C.L.; Brueckmann, I.; Scheela, C. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108, 7950-7955.
49. Dick, J.E. Looking ahead in cancer stem cell research. Nat. Biotechnol. 2009, 27, 44-46.
50. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumor formation by single human melanoma cells. Nature 2008, 456, 593-598.
51. Dingli, D.; Traulsen, A.; Pacheco, J.M. Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle 2007, 6, 461-466.
52. Vermeulen, L.; de SousaE Melo, F.; van der Heijden M., Cameron K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.; Todaro, M.; Merz, C.; Rodermond, H.; et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468-476.
53. Roesch, A.; Fukunaga-Kalabis, M.; Schmidt, E.C.; Zabierowski, S.E.; Brafford, P.A.; Vultur, A.; Basu, D.; Gimotty, P.; Vogt, T.; Herlyn, M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141, 583-594.
54. Giannoni, E.; Bianchini, F.; Masieri, L.; Serni, S.; Torre, E.; Galorini, L.; Chiarugi, P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70, 6945-6956.
55. Fiaschi, T.; Marini, A.; Giannoni, E.; Taddei, M.L.; Gandellini, P.; de Donatis, A.; Lanciotti, M.; Serni, S.; Cirri, P.; Chiarugi, P. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 2012, 72, 5130-5140.
56. Fiaschi, T.; Giannoni, E.; Taddei, M.L.; Cirri, P.; Marini, A.; Pintus, G.; Nativi, C.; Richichi, B.; Scozzafava, A.; Carta, F. et al. Carbonic anhydrase IX from cancer associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12, 1791-1801.
57. Hay, E.D. An overview of epithelio-mesenchymal transformation. Acta Anat. 1995, 154, 8-20.
58. Thiery, J.P.; Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7, 131-142.
59. Mani, S.A.; Guo, W.; Liao, M.J. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
60. Giannoni, E.; Bianchini, F.; Calorini, L.; Chiarugi, P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox. Signal. 2011, 14, 2361-2371.
61. Cirri, P.; Chiarugi, P. Cancer-associated-fibroblasts and tumor cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev.2012, 31, 195-208.
62. Piccirillo, S.G.; Reynolds, B.A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumor-initiating cells. Nature 2006, 444, 761-765.
63. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
64. Singh, S.K.; Hawkins, C.; Clarke, I.D. Identification of human brain tumor initiating cells. Nature 2004, 432, 396-401.
65. Cho, R.W.; Clarke, M.F. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 2008, 18, 48-53.
66. Bloushtain-Qimron, N.; Yao, J.; Snyder, E.L.; Shipitsin, M.; Campbell, L.L.; Mani, S.A. Cell type-specific DNA methylation patterns in the human breast. Proc. Natl. Acad. Sci. USA 2008, 105, 14076-14081.
67. Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11, 259-273.
68. Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA 2004, 101, 781-786.
69. Zheng, X.; Shen, G.; Yang, X.; Liu, W. Most C6 cells are cancer stem cells: Evidence from clonal and population analyses. Cancer Res. 2007, 67, 3691-3697.
70. Fukaya, R.; Ohta, S.; Yamaguchi, M.; Fujii, H.; Kawakami, Y. Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett. 2010, 291, 150-157.
71. Qiang, L.; Yang, Y.; Ma, Y.J.; Chen, F.H.; Zhang, L.B. Isolation and characterization of cancer stem like cells in human glioblasoma cell lines. Cancer Lett.2009, 279, 13-21.
72. Bale, A.E.; Yu, K.P. The hedgehog pathway and basal cell carcinomas. Hum. Mol. Genet. 2001, 10, 757-762.
73. Sheng, T.; Li, C.; Zhang, X.; Chi, S.; He, N.; Chen, K.; McCormick, F.; Gatalica, Z.; Xie, J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 2004, 3, 29.
74. Takebe, N.; Harris, P.J.; Warren, R.Q.; Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8, 97-106.
75. Rizzo, P.; Osipo, C.; Foreman, K.; Golde, T.; Osborne, B.; Miele, L. Rational targeting of Notch signalling in cancer. Oncogene 2008, 27, 5124-5131.
76. Ma, X.; Chen, K.; Huang, S.; Zhang, X.; Adegboyega, P.A.; Evers, B.M. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 2005, 26, 1698-1705.
77. Taylor, M.D.; Liu, L.; Raffel, C.; Hui, C.C.; Mainprize, T.G.; Zhang, X. Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 2002, 31, 306-310.
78. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837-1851.
79. Pardal, R.; Clarke, M.F.; Morrison, S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3, 895-902.
80. Rheinbay, E.; Suvà, M.L. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013, 3, 1567-1579.
81. Zhang, N.; Wei, P.; Gong, A. FoxM1 Promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20, 427-442.
82. Godlewski, J.; Nowicki, M.O.; Bronisz, A.; Williams, S.; Otsuki, A.; Nuovo, G. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008, 68, 9125-9130.
83. Beà, S.; Tort, F.; Pinyol, M.; Puig, X.; Hernández, L.; Hernández, S. BMI-1 gene amplification and over-expression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001, 61, 2409-2412.
84. Song, L.B.; Zeng, M.S.; Liao, W.T.; Zhang, L.; Mo, H.Y.; Liu, W.L. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66, 6225-6232.
85. Bhattacharya, R.; Nicoloso, M.; Arvizo, R.; Wang, E.; Cortez, A.; Rossi, S. MiR-15a and MiR-16 control Bmi-1expression in ovarian cancer. Cancer Res. 2009, 69, 9090-9095.
86. Lowell, E.M.; Westerman, B.A.; Ermilov, A.N. BMI1 is required for Hedgehog pathway- Driven medulloblastoma expansion. Neoplasia 2008, 10, 1343-1349.
87. Fujiwara, Y.; Yoshikawa, R.; Tao, L.; Tsujimura, T.; Sasako, M. Stemness signature of BMI1 and clinical outcome in esophageal cancer patients undergoing neoadjuvant chemoradiotherapy. J. Clin. Oncol. 2009, 27, 4572.
88. Jiang, L.; Li, J.; Song, L. Bmi-1, stem cells and cancer. Acta Biochim. Biophys. Sin. 2009, 41, 527-534.
89. Cleton-Jansen, A.M.; Anninga, J.K.; Briaire-de Bruijn, I.H.; Romeo, S. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. Br. J. Cancer 2009, 101, 1909-1918.
90. Yu, F.; Yao, H.; Zhu, P.; Zhang, X. Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
91. Carapancea, M.; Alexandru, O.; Fetea, A.S.; Dragutescu, L.; Castro, J.; Georgescu, A.; Popa-Wagner, A. Growth factor receptors signalling in glioblastoma cells: Therapeutic implications. J. Neurooncol. 2009, 92, 137-147.
92. Moitra, K.; Lou, H.; Dean, M. Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 2011, 89, 491-502.
93. Vermeulen, L.; de SousaE Melo, F.; Richel, D.J.; Medema, J.P. The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol. 2012, 13, e83-e89.
94. Zhou, B.B.; Zhang, H.; Damelin, M.; Geles, K.G.; Grindley, J.C.; Dirks, P.B. Tumor-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8, 806-823.
95. Naujokat, C.; Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012, 2012, 950658.
96. Cordon-Cardo, C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch- and Hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22, 373-388.
97. Rosen, J.M.; Jordan, C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324, 1670.
98. Katoh, M. Network of Wnt and other regulatory signalling cascades in pluripotent stem cells and cancer stem cells. Curr. Pharm. Biotechnol. 2011, 12, 160-170.
99. Zeng, G.; Apte, U.; Cieply, B. siRNA-mediated β-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007, 9, 951-959.
100. Adler, E.M. Inhibiting Wnt signalling. Sci. Signal. 2009, 2, ec326.
101. Stanton, B.Z.; Peng, L.F. Small-molecule modulators of the Sonic Hedgehog signalling pathway. Mol. Biosyst. 2010, 6, 44-54.
102. Wang, Q.; Huang, S.; Yang, L.; Zhao, L.; Yin, Y.; Liu, Z. Down-regulation of sonic hedgehog signaling pathway activity is involved in 5-fluorouracil-induced apoptosis and motility inhibition in Hep3B cells. Acta Biochim. Biophys. Sin. 2008, 40, 819-829.
103. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang W. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136, 1012-1024.
104. Chen, Y.; Yu, D.; Zhang, H.; He, H.; Zhang, C. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int. J. Biol. Sci. 2012, 8, 992-1004.
105. Bin, B.; Asfar, A.; Amro, A.; Aamir, A. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J. Biol. Chem. 2014, doi:10.1074/jbc.M113.532887.
106. Zhu, Z.; Hao, X.; Yan, M.; Yao, M.; Ge, C.; Gu, J.; Li, J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126, 2067-2078.
107. Kurtz, J.E.; Dufour, P. Adecatumumab: An anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin. Biol. Ther. 2010, 10, 951-958.
108. Motohashi, T.; Aoki, H.; Chiba, K. Multipotent cell fate of neural crest-like cells derived from embryonic stem cells. Stem Cells 2007, 25, 402-410.
109. O'Brien, C.A.; Kreso, A.; Jamieson, C.H. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16, 3113-3120.
110. Alison, M.R.; Lim, S.M.; Nicholson, L.J. Cancer stem cells: Problems for therapy? J. Pathol. 2010, 223, 148-162.
111. Hermann, P.C.; Trabulo, S.M.; Sainz, B., Jr.; Balic, A.; Garcia, E.; Hahn, S.A. Multimodal treatment eliminates cancer stem cells and leads to long-term survival in primary human pancreatic cancer tissue xenografts. PLoS One 2013, 8, e66371.
112. Chen, G.; Xu, S.; Renko, K.; Derwahl, M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrin. Metab. 2012, 97, 1-11.
113. Chan, C.H.; Morrow, J.K.; Li, C.F.; Gao, Y.; Jin, G.; Moten, A. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 2013, 154, 556-568.
114. Alisi, A.; Cho, W.C.; Locatelli, F.; Fruci, D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int. J. Mol. Sci. 2013, 14, 24706-24725.
115. Gottesman, M.M. Mechanisms of cancer drug resistance. Ann. Rev. Med. 2002, 53, 615-627.
116. Ullah, M.F. Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy. Asian Pac. J. Cancer Prev. 2008, 9, 1-6.
117. Science Daily. Available online: http://www.sciencedaily.com/releases/2012/09/120910122114.htm (accessed on 10 October 2013).
118. Ruck, P.; Xiao, J.C.; Pietsch, T.; von Schweinitz, D.; Kaiserling, E. Hepatic stem-like cells in hepatoblastoma: Expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology 1997, 31, 324-329.